
The Mesothelioma Center News – Page 22
-
Research & Clinical TrialsThe U.S. Food and Drug Administration has granted orphan drug designation to ONCOFID-P for the treatment of malignant pleural mesothelioma, a step…
-
Research & Clinical Trials
Researcher Hopes to Improve Tumor Treating Fields for Mesothelioma
Dr. Maurizio D’Incalci already has seen Tumor Treating Fields working for patients with malignant pleural mesothelioma, and applauded the U.S. Food and… -
Research & Clinical Trials
CAR T-Cell Therapy Showing Promise with Pleural Mesothelioma
Memorial Sloan Kettering Cancer Center continues its drive toward a future that may involve innovative CAR T-cell therapy as part of standard-of-care treatment… -
Legislation & Litigation
Johnson & Johnson Weighs Options for Talc Liabilities
Johnson & Johnson is considering the creation of a new subsidiary to absorb its widespread asbestos liabilities, according to reports in The Wall… -
Research & Clinical Trials
New Drug Combination Shows Promise for Peritoneal Mesothelioma
Researchers at MD Anderson Cancer Center in Houston have uncovered a new, promising treatment option for patients with peritoneal mesothelioma, potentially filling… -
Research & Clinical Trials
Mesothelioma Research Grants Focus on Immunotherapy
It comes as no surprise that immunotherapy is the common theme of the latest batch of the Mesothelioma Applied Research Foundation’s $100,000 grants. -
Research & Clinical Trials
GPS Vaccine Plus Opdivo Shows Promise for Pleural Mesothelioma
A novel, targeted cancer vaccine combined with the immunotherapy drug Opdivo has shown surprising efficacy for mesothelioma patients whose disease no longer… -
Research & Clinical Trials
Mayo Clinic Opens Novel Clinical Trial for Mesothelioma
Researchers at the much-acclaimed Mayo Clinic in Rochester, Minnesota, have opened the first clinical trial for mesothelioma patients that combines a recently approved… -
Research & Clinical Trials
Clinical Trial Shows Benefits of Vinorelbine for Mesothelioma
Mesothelioma specialist Dr. Dean Fennell has strongly endorsed the use of vinorelbine as a second-line treatment for patients with relapsed disease. He… -
Research & Clinical Trials
ONCOS-102 Vaccine Showing Impressive Results for Mesothelioma
The novel immunotherapy vaccine ONCOS-102 may become the answer for the large percentage of mesothelioma cancer patients who fail to respond to a…